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EXTENSIVE CLINICAL EXPERIENCE
Absence of Increased Height Velocity in the First Year of
Life in Untreated Children with Simple Virilizing
Congenital Adrenal Hyperplasia
Hedi L. Claahsen-van der Grinten, Kees Noordam, George F. Borm, and Barto J. Otten
Departments of Metabolic and Endocrine Diseases (H.L.C.-v.d.G., K.N., B.J.O.) and Epidemiology and Biostatistics (G.F.B.),
Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
Context: In congenital adrenal hyperplasia (CAH), elevation of ad-
renal androgens leads to accelerated growth and bone maturation
with compromised adult height.
Objective/Patients: The objective of the study was to analyze ret-
rospectively early growth and bonematuration in 17untreated simple
virilizing (SV) CAH patients.
Setting: The study was conducted at Radboud University Nijmegen
Medical Centre.
Interventions: Growth data were collected until time of diagnosis.
Height was expressed as height SD score and corrected for target
height. Bone maturation was determined and expressed as bone age
acceleration.
Main Outcome Measures: Growth pattern and bone maturation
were measured before the diagnosis.
Results: In the term group (n  11), there was no increase in height
SD score and corrected for target height in the first year of life [0.1
SD/yr; 95% confidence interval (CI) 0.5, 0.3] with a consecutive
significant (P  0.001) increase up to 0.9 SD/yr (95% CI 0.7, 1.0). In
the premature group (n 3), there was a catch-up growth of 1.6 SD/yr
(95%CI 0.9, 2.3) in the first year followed by a growth of 1.1 SD/yr (95%
CI 0.9, 1.5) in the following years. There was a positive linear cor-
relation between bone age acceleration and age of diagnosis (r 0.8).
Conclusions:Height velocity and bonematuration are not increased
in untreated children with mild forms of SV CAH in the first year of
life. After this period there is a progressive increase in height velocity
and bone maturation in strong relation to the duration of androgen
exposition. This observation has implications for the dose of glucocor-
ticoids to be used in SV CAH patients in the first year of life. (J Clin
Endocrinol Metab 91: 1205–1209, 2006)
CONGENITAL ADRENAL HYPERPLASIA (CAH) isone of the most common autosomal recessive endo-
crine disorders with an incidence of the classical form at
1:10,000 (1, 2). In most cases, the disease is caused by 21-
hydroxylase deficiency. As a result of the enzyme deficiency,
the synthesis of cortisol and mostly also that of aldosterone
is impaired. Consequently, the secretion of ACTH by the
pituitary gland increases, leading to hyperplasia of the ad-
renal cortex and excess of androgen production. The gene
encoding for 21-hydroxylase is well known, and the diag-
nosis CAH can be easily confirmed by mutation analysis.
There is a strong genotype-phenotype correlation reported to
be up to 80–90% (3–5).
The clinical symptoms of CAH depend on the degree of
enzyme deficiency. In the most severe form, the classic salt
wasting (SW) form, the enzyme activity is less then 1% lead-
ing to prenatal virilization in female patients and life-threat-
ening SW in both sexes. An enzyme activity of 1–5% is
enough to preserve aldosterone synthesis leading to the clas-
sic simple virilizing (SV) form. Inmost of themale cases with
the SV form of CAH, patients are not detected in the neonatal
period but present after several years with signs of androgen
excess leading to pseudo-precocious puberty with increased
growth velocity, pubic hair development, and enlargement
of the external genitalia. The mildest form of CAH, the late-
onset type, can present alsowith pseudo-precocious puberty,
irregular menstruation, hirsutism, and infertility. This form
of CAH can be easily missed, especially in male patients. The
treatment of CAH consists of substitution of cortisol to pre-
vent Addison crisis and suppress the adrenal androgen over-
production. In the SW form, aldosterone also has to be sub-
stituted as well.
The growth pattern of treated children with SW or SV CAH
is described in several studies (6–10). It is well known that
adrenal hypersecretion of androgens causes increased growth
velocity and bone age acceleration. Therefore, adequate sup-
pression of androgens by treatment with glucocorticoids is im-
portant; however, oversuppression resulting in Cushing syn-
drome and growth retardation has to be avoided. Previous
reports on the growth pattern in children with CAH suggested
that the height velocity is not increased in the first years of life,
even in the untreated patient group (11–13).
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We therefore investigated retrospectively our group of
patients with SV CAH retrospectively to define their growth
pattern before the diagnosis. Furthermore, we evaluated the
age of the onset of symptoms, the presence of associated
clinical features, and the bone maturation at the time of the
diagnosis.
Patients and Methods
Patients
We evaluated 17 patients with SV CAH (11 males and six females).
None of the patients was treated with glucocorticoids before the time of
diagnosis. Two patients (no. 12 and 13) are sisters.
The diagnosis SV CAHwas based on clinical and biochemical criteria
(i.e. elevated levels of 17-hydroxyprogesterone and androstenedione,
abnormal urinary steroid profile, ACTH stimulation test) and was con-
firmed by mutation analysis (see Table 1). SW crisis has not been re-
ported in any of the patients.
The I172N mutation, which is associated with the SV form of CAH,
was detected in all but one patient (no. 16) in at least one allele. Four
patients were homozygous for the I172N mutation. Patient 16 with the
clinical features of the SV form of CAH had a homozygous deletion/
conversion, which is typically associated with the SW form of CAH.
Three patients were born prematurely (no. 10, 13, and 14).
Clinical features and growth analysis
The age of diagnosis and clinical symptoms were obtained from the
patient’s medical records. The growth data from birth to the first pre-
sentation in our clinic were collected from the well-baby clinical reports.
Sufficient growth data were available in 14 patients (six females and
eight males): five to 15 growth measurements per patient were available
before the diagnosis, dependent on the age of the diagnosis. Height was
expressed as height sd score according to the national references (14) and
corrected for target height (HSDS-THSDS). Bone maturation at the time
of diagnosis was determined according to the atlas of Greulich and Pyle
and expressed as bone age acceleration (BAc bone age calendar age).
Statistical analysis
Because only limited data for the height (HSDS-THSDS) of untreated
patients were available for the age over 4 yr, we limited our analysis to
the period 0–4 yr. To account for the longitudinal character of the study,
linear mixed models with random factor patient were used for the
analysis of the growth
In a preliminary analysis, the statistical model was selected by in-
cluding the fixed effects age, prematurity, sex, and the interaction be-
tween age and the other factors in the model. Because the relationship
between age and HSDS-THSDS may not be linear, age was included as
a spline function with knots at 1 and 2 yr of age. This analysis showed
a strong interaction between age and prematurity; therefore, the growth
of the premature and mature children was analyzed separately. It also
showed that a spline function with only one knot at 1 yr could ade-
quately describe the data. Such a function consists of two straight lines,
one for the growth during the first year after birth and another one for
the growth between the age of 1 and 4 yr. As a result, in the final analysis,
the model included the fixed effects age up to 1 yr, age over 1 yr, and
sex. This model was used to derive estimates for the growth during and
after the first year.
Simple linear regression analysis was performed to evaluate the re-
lationship between BAc and age at diagnosis. Ninety-five percent con-
fidence intervals were calculated. The significance level for statistical
testing was set at P  0.05 (two sided).
Results
Clinical presentation and growth analysis
The data on the clinical presentation are summarized in
Table 1. Fifteen of the 17 children presented with increased
growth velocity. The age of reported growth accelerationwas
18 months or older. The other two patients (no. 16 and 17)
were detected at the age of 17 months and 23 months and
presented with clitoral hypertrophy and pubic hair devel-
opment without a history of increased height velocity. Pubic
hair was noted in 11 children. At the time of the diagnosis,
enlargement of external genitalia was found in 11 children
(seven boys and four girls). Acne was detected in only two
patients. Axillary hair or hirsutism was not reported in any
of the patients.
The median age of onset of the first symptoms was 28
months (range 12–46 months) in girls and 51 months (range
18–86 months) in boys.
Birth length corrected for gestational age was greater than
TABLE 1. Mutation analysis, clinical presentation, and BAc at time of diagnosis in 17 patients with SV CAH
Patient
no. Sex
Mutation analysis Symptoms at
time of
diagnosisa
Age at first
symptoms
(yr:month)
BAcb at
diagnosis
(yr:month)
Birth weight (g)
with SDSc
Birth length (cm)
with SDSc
Gestational
age (wk)Allele 1 Allele 2
1 M Intron2 I172N 1, 3 6:2 2880 49
2 M I172N R356W 2, 3 1:6 4:8 2700 48
3 M Intron2 I172N 1, 3 6:2 5:2 3380 (0.6) 50 (0.6) 40
4 M Del-Conv I172N 1, 2, 3 3:10 4:2 3975 (0.7) 50 (0.6) 40
5 M I172N I172N 1, 3 4:0 7:1 3250 (0.1) 50 (0.1) 38
6 M Del-Conv I172N 1, 2, 3 3:1 3:4 3770 (0.05) 57 (3.0) 41
7 M I172N 1235N,V237E,M239K 1, 2, 3, 4 2:11 2:5 3500 (0.3) 40
8 M Del-Conv I172N 1, 3, 4 5:10 5:2 3940 (0.7) 53 (1.1) 40
9 M I172N Del-Conv 2, 3 3:5 6:0 3850 (0.5) 52 (0.5) 40
10 M I172N Q318X 2, 3 3:0 5:1 2350 (1.3) 48 (0.1) 36
11 M I172N I172N 1, 2, 3 7:2 7:0
12 F I172N I172N 1, 2, 3 3:10 3:8 3500 (0.03) 54 (2.2) 40
13 F I172N I172N 2, 3 2:8 0:8 2100 (0.1) 43 (0.6) 33
14 F Intron2 I172N 1, 2, 3 1:6 2750 (0.6) 47 (0.7) 37
15 F Del-Conv I172N 3 3:4 1:8 3000 (1.2) 48 (1.3) 40
16 F Del-Conv Del-Conv 2 1:0 0:1 3500 (0.2) 41
17 F G110nt I172N 1 1:11 3300 (0.5) 54 (2.2) 40
M, Male; F, female.
a Symptoms: 1, pubic hair; 2, enlarged external genital; 3, increased height velocity; 4, acne; 5, axillary hair.
b BAc, Bone age  calendar age.
c SDS was calculated according to Niklasson et al. (33).
1206 J Clin Endocrinol Metab, April 2006, 91(4):1205–1209 Claahsen-van der Grinten et al. • Height Velocity in Untreated CAH Infants
1.3 sd score (SDS) in all children except for one child (no.
15) with a birth length of 1.3 SDS and early stunting in the
follow-up with weight and length decreasing to below 2.0
SDS. Three patients had a birth weight greater than 2 SDS.
The growth data of 14 patients with sufficient growth data
are summarized in Fig. 1. In the term group (n  11), there
was no significant increase in height velocity in the first year
[0.1 sd/yr; 95% confidence interval (CI) 0.5, 0.3] with a
consecutive significant (P  0.001) increase up to 0.9 sd/yr
(95%CI 0.7, 1.0). In premature group (n 3) therewas a catch
up growth of 1.6 sd/yr (95% CI 0.9, 2.3) in the first year
followed by a growth of 1.1 sd/yr (95% CI 0.7, 1.5) in the
following years.
Bone maturation at time of diagnosis was determined in
14 of the 17 patients (Fig. 2).We found a strong positive linear
correlation between bone maturation and age of diagnosis
(Pearson’s correlation coefficient  0.8). BAc increase was
1.06/yr (P  0.01).
Discussion
In our group of patientswith SVCAH, themost prominent
symptoms at time of diagnosis were increased height veloc-
ity, pubic hair, and enlargement of external genitalia. These
observations are similar to other studies. Surprisinglywe did
not find any axillary hair development or hirsutism, sug-
gesting a higher threshold for androgens in the axillary
region.
Increased height velocity is one of the most prominent
symptoms of androgen excess in childhood. In prepubertal
CAHpatients, failure to suppress adrenal androgens leads to
accelerated growth and bone maturation with compromised
adult height. Treatment with glucocorticoids aims to sup-
press ACTH and androgens and to restore normal growth
and maturation (1, 6–10).
The results of our study, demonstrating the absence of
increased height velocity in patients with SV CAH at least in
the first 12 months of postnatal life, suggests the presence of
relative resistance to androgen excess. After this period there
is a progressive increase of growth velocity and bone mat-
uration in a strong relation to the duration of androgen
exposure. Several authors described the lack of growth ac-
celeration in the first year of life as well. Aceto et al. (15)
described three girls with CAH and normal height and bone
age at time of diagnosis at 21, 24, and 42 months of age
without information about longitudinal growth data, paren-
tal height, or the type of CAH. Another study by Thilen et al.
(12) in 14 childrenwith SVCAHshowedno increase in height
velocity until the age of 18 months; however, height was not
corrected for target height, and no statistical analysis was
performed.
A similar growth pattern can be observed in other patho-
logical conditions with high androgen levels like in familiar
testitoxicosis (16, 17). Also in normal males, the temporary
high levels of testosterone at the age of 6 wk to 6 months in
their minipuberty seem to have no effect on the growth
velocity in boys, compared with girls.
The reason for the lack of increased height velocity of CAH
patients in the early life is not well understood.
It is well known that androgens act on the bone mainly
after being aromatized to estrogens; however, direct effects
are described as well (18, 19). Van der Eerden et al. (20)
detected an androgen receptor (AR) in the tibial growth plate
of male and female rats with a significant higher expression
rate in male than female rats during sexual maturation with
increased testosterone levels. They found that testosterone
can either up-regulate or down-regulate AR mRNA in a
dose-dependent manner (20). The insensitivity of bone to
androgens in the first year of life can hypothetically be ex-
plained by temporary down-regulating or limited expression
of the AR in this period (21).
FIG. 2. BAc at age of diagnosis in 14 patients with SVCAH (r 0.84).
FIG. 1. Growth pattern before diagnosis in 14 patients with SV CAH
in the first 4 yr of life. Height is expressed as height SD score and
corrected for target height (HSDS-THSDS). The solid lines represent
the termborn group (n 11), thedotted lines represent the premature
born group (n  3). The thick solid line shows the estimated mean of
the HSDS-THSDS of the term group, thick dotted line of the P/SGA
group.
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Another possible explanation of increased growth velocity
by sex hormones might be the interference with the GH/IGF
axis. Sex hormones, mainly estrogens, increase pulse ampli-
tude and the amount of GH secreted per pulse (22). It is
suggested in the infancy-childhood-puberty model that the
infancy growth in the first year of life seems to be relatively
independent of GH (23, 24). Therefore, in this period any
action of androgens by this pathway may not result in in-
creased growth velocity. However, several studies (25, 26)
show that GH has some influence also in the first year of life
as demonstrated by growth failure of children with congen-
ital GH deficiency.
There are not much data about the effect of androgen
excess in utero on prenatal growth and bone maturation.
Some studies (6, 27) show that the birth length in patients
with CAH is slightly elevated, independent of the degree of
virilization in girls or the postnatal androgen levels in boys.
Therefore, androgen excess in utero seems to have no strong
effect on the prenatal growth and bone maturation. In our
patients birth weight and length were mostly within the
normal range.
The absence of growth acceleration seems to be indepen-
dent of the severity of the disease. Personal observations of
a patient with SWCAH and urethral valves who was treated
only with salt substitution in the first 3 yr of life showed no
increase in growth velocity or bone maturation (our unpub-
lished data).
There is no evidence that higher androgens in the first year
of life can cause infertility in later years. It is well known that
fertility in women with CAH is impaired due to several
factors: mechanical factors after genital surgery, adrenal
overproduction with disturbing ovarian activity, polycystic
ovarian syndrome, or ovarian adrenal rests. It is not known
whether higher androgens in the first year of life can also
contribute to these factors. Behavioral problems are mostly
the result of prenatal exposure of androgens and not of
postnatal exposure (28, 29). A prospective study to analyze
reproductive problems in this groupof patients could be very
helpful.
In our population the androgen levels in the first yearwere
not measured because the diagnosis was made in later life.
Therefore elevated androgens were not established. It is
known that in SV CAHpatients androgen levels are elevated
in utero and after birth. The 21-hydroxylase activity in this
group is less than 5%, leading to elevated serum 17 hy-
droxyprogesterone and androstenedione levels. This be-
comes visible in girls with SV CAH, who present with signs
of virilization after birth. However, it is just possible that in
this situation the androgen levels are not high enough to see
any effect on the growth velocity in early life.
Although the reason for the absence of increased height
velocity in the first year of life in SV CAH patients is not
completely understood, our observations have important im-
plications for the first year treatment of children with CAH.
In prepubertal children, the recommended cortisol replace-
ment is hydrocortisone in doses of 10–20 mg/m2d in two or
three divided doses (30). This advice is based on the clinical
experience with the general premise to use the lowest pos-
sible dosage. However, the glucocorticoid dosages used in
daily practice in infancy are much higher (9–37.5 mg/m2d)
(31). These doses exceed physiological levels of cortisol se-
cretion, which are 6–8 mg/m2d in children and adolescents
and are necessary to adequately suppress adrenal androgens
and prevent growth acceleration.
However because of the absence of increased growth ve-
locity and bone maturation in the first year of life as dem-
onstrated in our study, suppression of androgens as required
in later years to prevent growth acceleration is not necessary,
and much lower doses of glucocorticoids are sufficient for
adequate treatment. Moreover, in an earlier study (32), we
demonstrated the high sensitivity of glucocorticoid with re-
spect to growth retardation, especially in the first year of life.
These two arguments augment for a recommendation of
using more physiological glucocorticoid doses in early age.
Further prospective studieswill be done to evaluate the effect
of this treatment on growth and fertility in later life.
Conclusion
Our study demonstrates the absence of increased growth
velocity and bonematuration in the first year of life untreated
children with mild forms of SV CAH. After this period there
is a progressive increase in height velocity bone maturation
with a strong correlation with the duration of androgen
exposure. This observation has implications for the dose of
glucocorticoids to be used in SV CAH patients in the first
year of life.
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